{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:00:56Z","timestamp":1767142856840,"version":"build-2238731810"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s13318-021-00706-z","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T03:03:36Z","timestamp":1627614216000},"page":"601-611","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1100-6806","authenticated-orcid":false,"given":"Irina","family":"Kareva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anup","family":"Zutshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina Vazquez","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orestis","family":"Papasouliotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,30]]},"reference":[{"issue":"2","key":"706_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40262-016-0426-z","volume":"56","author":"T Yu","year":"2017","unstructured":"Yu T, Enioutina EY, Brunner HI, Vinks AA, Sherwin CM. Clinical pharmacokinetics and pharmacodynamics of biologic therapeutics for treatment of systemic lupus erythematosus. Clin Pharm. 2017;56(2):107\u201325.","journal-title":"Clin Pharm"},{"issue":"3","key":"706_CR2","first-page":"211","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. Trial of anifrolumab in active systemic lupus erythematosus. NEJM Mass Med Soc. 2020;382(3):211\u201321.","journal-title":"NEJM Mass Med Soc"},{"issue":"3","key":"706_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1046\/j.1365-2710.2000.00284.x","volume":"25","author":"D Hougardy","year":"2000","unstructured":"Hougardy D, Peterson G, Bleasel M, Randall C. Is enough attention being given to the adverse effects of corticosteroid therapy? J Clin Pharma Ther. 2000;25(3):227\u201334.","journal-title":"J Clin Pharma Ther"},{"issue":"1","key":"706_CR4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1365-2133.2007.07950.x","volume":"157","author":"L Fardet","year":"2007","unstructured":"Fardet L, Flahault A, Kettaneh A, Tiev K-P, G\u00e9n\u00e9reau T, Tol\u00e9dano C, et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient\u2019s opinion. Brit J Dermatol. 2007;157(1):142\u20138.","journal-title":"Brit J Dermatol"},{"issue":"2","key":"706_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/BOR.0b013e3282f51031","volume":"20","author":"AK McDonough","year":"2008","unstructured":"McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol. 2008;20(2):131\u20137.","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"706_CR6","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.jaci.2015.04.049","volume":"136","author":"FA Bonilla","year":"2015","unstructured":"Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186\u2013205.","journal-title":"J Allergy Clin Immunol"},{"key":"706_CR7","doi-asserted-by":"crossref","unstructured":"De Vries E, European Society for Immunodeficiencies (ESID) Members. Patient-centred screening for primary immunodeficiency, a multi-stage diagnostic protocol designed for non-immunologists: 2011 update. Clin Exp Immunol. 2012;167(1):108\u201319.","DOI":"10.1111\/j.1365-2249.2011.04461.x"},{"issue":"1","key":"706_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s10875-013-9954-6","volume":"34","author":"BT Costa-Carvalho","year":"2014","unstructured":"Costa-Carvalho BT, Grumach AS, Franco JL, Espinosa-Rosales FJ, Leiva LE, King A, et al. Attending to warning signs of primary immunodeficiency diseases across the range of clinical practice. J Clin Immunol. 2014;34(1):10\u201322.","journal-title":"J Clin Immunol"},{"issue":"2","key":"706_CR9","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s12016-014-8412-4","volume":"46","author":"BA Locke","year":"2014","unstructured":"Locke BA, Dasu T, Verbsky JW. Laboratory diagnosis of primary immunodeficiencies. Clin Rev Allergy Immunol. 2014;46(2):154\u201368.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"10","key":"706_CR10","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/cid\/ciu646","volume":"59","author":"C Aguilar","year":"2014","unstructured":"Aguilar C, Malphettes M, Donadieu J, Chandesris O, Coignard-Biehler H, Catherinot E, et al. Prevention of infections during primary immunodeficiency. Clin Infect Dis. 2014;59(10):1462\u201370.","journal-title":"Clin Infect Dis"},{"key":"706_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","volume":"47","author":"GJ Weiner","year":"2010","unstructured":"Weiner GJ. Rituximab: mechanism of action. Sem Hematol. 2010;47(2):115\u201323.","journal-title":"Sem Hematol"},{"issue":"8","key":"706_CR12","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/imj.13136","volume":"46","author":"P Kotagiri","year":"2016","unstructured":"Kotagiri P, Martin A, Hughes P, Becker G, Nicholls K. Single-dose rituximab in refractory lupus nephritis. Int Med J. 2016;46(8):899\u2013901.","journal-title":"Int Med J"},{"issue":"4","key":"706_CR13","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215\u201326.","journal-title":"Arthritis Rheum"},{"issue":"15S","key":"706_CR14","doi-asserted-by":"publisher","first-page":"8593","DOI":"10.1200\/jco.2009.27.15_suppl.8593","volume":"27","author":"J Kaufman","year":"2009","unstructured":"Kaufman J, Niesvizky R, Stadtmauer E, Chanan-Khan A, Siegel D, Horne H, et al. Dose-escalation trial of milatuzumab (humanized anti-CD74 monoclonal antibody) in multiple myeloma. J Clin Oncol Am Soc Clin Oncol. 2009;27(15S):8593\u20138593.","journal-title":"J Clin Oncol Am Soc Clin Oncol"},{"issue":"2","key":"706_CR15","doi-asserted-by":"publisher","first-page":"R54","DOI":"10.1186\/ar3767","volume":"14","author":"D Fr\u00f6lich","year":"2012","unstructured":"Fr\u00f6lich D, Bla\u03b2feld D, Reiter K, Giesecke C, Daridon C, Mei HE, et al. The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression. Arthritis Res Ther BioMed Cent. 2012;14(2):R54.","journal-title":"Arthritis Res Ther BioMed Cent"},{"issue":"1","key":"706_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1517\/13543780903463854","volume":"19","author":"Z Berkova","year":"2010","unstructured":"Berkova Z, Tao R-H, Samaniego F. Milatuzumab\u2014a promising new immunotherapeutic agent. Exp Opin Investig Drugs. 2010;19(1):141\u20139.","journal-title":"Exp Opin Investig Drugs"},{"issue":"9767","key":"706_CR17","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzm\u00e1n RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721\u201331.","journal-title":"Lancet"},{"key":"706_CR18","first-page":"1331","volume":"9","author":"E Cogollo","year":"2015","unstructured":"Cogollo E, Silva MA, Isenberg D. Profile of atacicept and its potential in the treatment of systemic lupus erythematosus. Drug Des Dev Ther. 2015;9:1331.","journal-title":"Drug Des Dev Ther"},{"issue":"10","key":"706_CR19","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. NEJM. 2017;376(10):917\u201327.","journal-title":"NEJM"},{"issue":"8","key":"706_CR20","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. NEJM. 2016;375(8):754\u201366.","journal-title":"NEJM"},{"issue":"3","key":"706_CR21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/rheumatology\/keq287","volume":"50","author":"M Schiff","year":"2010","unstructured":"Schiff M. Abatacept treatment for rheumatoid arthritis. Rheumatology. 2010;50(3):437\u201349.","journal-title":"Rheumatology"},{"issue":"6","key":"706_CR22","doi-asserted-by":"publisher","first-page":"e100324","DOI":"10.1371\/journal.pone.0100324","volume":"9","author":"SS Duraisingham","year":"2014","unstructured":"Duraisingham SS, Buckland M, Dempster J, Lorenzo L, Grigoriadou S, Longhurst HJ. Primary vs. secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement. PLoS\u00a0One. 2014;9(6):e100324.","journal-title":"PLoS\u00a0One"},{"issue":"5","key":"706_CR23","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1586\/1744666X.2014.902314","volume":"10","author":"SS Duraisingham","year":"2014","unstructured":"Duraisingham SS, Buckland MS, Grigoriadou S, Longhurst HJ. Secondary antibody deficiency. Exp Rev Clin Immunol. 2014;10(5):583\u201391.","journal-title":"Exp Rev Clin Immunol"},{"issue":"6","key":"706_CR24","doi-asserted-by":"publisher","first-page":"571","DOI":"10.7861\/clinmedicine.16-6-571","volume":"16","author":"S Srivastava","year":"2016","unstructured":"Srivastava S, Wood P. Secondary antibody deficiency\u2014causes and approach to diagnosis. Clin Med. 2016;16(6):571\u20136.","journal-title":"Clin Med"},{"issue":"3","key":"706_CR25","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1128\/CMR.00001-09","volume":"22","author":"AJ Fried","year":"2009","unstructured":"Fried AJ, Bonilla FA. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Rev. 2009;22(3):396\u2013414.","journal-title":"Clin Microbiol Rev"},{"issue":"7","key":"706_CR26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nri3466","volume":"13","author":"A Durandy","year":"2013","unstructured":"Durandy A, Kracker S, Fischer A. Primary antibody deficiencies. Nat Rev Immunol. 2013;13(7):519\u201333.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"706_CR27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/01.md.0000229482.27398.ad","volume":"85","author":"JA Winkelstein","year":"2006","unstructured":"Winkelstein JA, Marino MC, Lederman HM, Jones SM, Sullivan K, Burks AW, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine. 2006;85(4):193\u2013202.","journal-title":"Medicine"},{"issue":"1","key":"706_CR28","first-page":"77","volume":"111","author":"C Wehr","year":"2008","unstructured":"Wehr C, Kivioja T, Schmitt C, Ferry B, Witte T, Eren E, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood Am Soc Hematol. 2008;111(1):77\u201385.","journal-title":"Blood Am Soc Hematol"},{"issue":"7","key":"706_CR29","doi-asserted-by":"publisher","first-page":"e184169","DOI":"10.1001\/jamanetworkopen.2018.4169","volume":"1","author":"S Barmettler","year":"2018","unstructured":"Barmettler S, Ong M-S, Farmer JR, Choi H, Walter J. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open. 2018;1(7):e184169\u2013e184169.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"706_CR30","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S1081-1206(10)61142-8","volume":"94","author":"FA Bonilla","year":"2005","unstructured":"Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol. 2005;94(5):S1\u201363.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"706_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/2040622313485275","volume":"4","author":"K Orlicka","year":"2013","unstructured":"Orlicka K, Barnes E, Culver EL. Prevention of infection caused by immunosuppressive drugs in gastroenterology. Ther Adv Chronic Dis. 2013;4(4):167\u201385.","journal-title":"Ther Adv Chronic Dis"},{"issue":"2","key":"706_CR32","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1208\/s12248-016-0004-1","volume":"19","author":"A Tiwari","year":"2017","unstructured":"Tiwari A, Abraham AK, Harrold JM, Zutshi A, Singh P. Optimal affinity of a monoclonal antibody: guiding principles using mechanistic modeling. AAPS J. 2017;19(2):510\u20139.","journal-title":"AAPS J"},{"issue":"3","key":"706_CR33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1046\/j.1365-2125.1998.00676.x","volume":"45","author":"A Sharma","year":"1998","unstructured":"Sharma A, Jusko WJ. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Brit J Clin Pharmacol. 1998;45(3):229\u201339.","journal-title":"Brit J Clin Pharmacol"},{"issue":"1","key":"706_CR34","first-page":"1","volume":"42","author":"VL Chudasama","year":"2015","unstructured":"Chudasama VL, Zutshi A, Singh P, Abraham AK, Mager DE, Harrold JM. Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodies. J PKPD. 2015;42(1):1\u201318.","journal-title":"J PKPD"},{"issue":"2","key":"706_CR35","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/art.40360","volume":"70","author":"JT Merrill","year":"2018","unstructured":"Merrill JT, Wallace DJ, Wax S, Kao A, Fraser PA, Chang P, et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase II b study. Arthritis Rheumatol. 2018;70(2):266\u201376.","journal-title":"Arthritis Rheumatol"},{"key":"706_CR36","doi-asserted-by":"crossref","unstructured":"Cancro M. The BLyS\/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity. Ann Rhem Dis. 2006;65(Suppl 3):iii34\u20136.","DOI":"10.1136\/ard.2006.058412"},{"key":"706_CR37","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1136\/annrheumdis-2015-eular.3504","volume":"74","author":"O Papasouliotis","year":"2015","unstructured":"Papasouliotis O, Yalkinoglu \u00d6, Golob M, Willen D, Girard P. AB0529 population pharmacokinetics of atacicept in systemic lupus erythematosus (SLE). Ann Rheum Dis. 2015;74:1077.","journal-title":"Ann Rheum Dis"},{"key":"706_CR38","unstructured":"Pitsui M, Papasouliotis O, Farrell C, Girard P, Yalkinoglu O, Vazquez-Mateo C. Population pharmacokinetics of atacicept in systemic lupus erythematosus (SLE)\u2014an analysis of three clinical trials. Arthritis Rheumatol. 2019:71(Suppl 10). https:\/\/acrabstracts.org\/abstract\/population-pharmacokinetics-of-atacicept-in-systemiclupus-erythematosus-sle-an-analysis-of-three-clinical-trials\/"},{"issue":"1","key":"706_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s13318-019-00575-7","volume":"45","author":"D Willen","year":"2020","unstructured":"Willen D, Uhl W, Wolna P, Papasouliotis O, Yalkinoglu \u00d6. Safety, tolerability, pharmacokinetics, and pharmacodynamics of atacicept in a randomized trial in healthy Caucasian and Japanese subjects. Eur J Drug Metab Pharm. 2020;45(1):27\u201340.","journal-title":"Eur J Drug Metab Pharm"},{"key":"706_CR40","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","volume":"57","author":"DM Roberts","year":"2015","unstructured":"Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, et al. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun. 2015;57:60\u20135.","journal-title":"J Autoimmun"},{"issue":"1","key":"706_CR41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12969-019-0365-y","volume":"17","author":"AM Khojah","year":"2019","unstructured":"Khojah AM, Miller ML, Klein-Gitelman MS, Curran ML, Hans V, Pachman LM, Fuleihan RL. Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases. Pediatr Rheumatol Online J. 2019;17(1):61.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"4","key":"706_CR42","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/ajt.13557","volume":"16","author":"M Mujtaba","year":"2016","unstructured":"Mujtaba M, Komocsar W, Nantz E, Samaniego M, Henson S, Hague J, et al. Effect of treatment with tabalumab, a B cell-activating factor inhibitor, on highly sensitized patients with end-stage renal disease awaiting transplantation. Am J Transplant. 2016;16(4):1266\u201375.","journal-title":"Am J Transplant"},{"issue":"6","key":"706_CR43","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/annrheumdis-2018-213032","volume":"77","author":"JT Merrill","year":"2018","unstructured":"Merrill JT, Shanahan WR, Scheinberg M, Kalunian KC, Wofsy D, Martin RS. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018;77(6):883\u20139.","journal-title":"Ann Rheum Dis"}],"updated-by":[{"DOI":"10.1007\/s13318-021-00719-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000}}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-021-00706-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-021-00706-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-021-00706-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T04:37:31Z","timestamp":1637123851000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-021-00706-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,30]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["706"],"URL":"https:\/\/doi.org\/10.1007\/s13318-021-00706-z","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,30]]},"assertion":[{"value":"11 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13318-021-00719-8","URL":"https:\/\/doi.org\/10.1007\/s13318-021-00719-8","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Writing and critical review of the manuscript: all authors. Study design: IK. Population PK modeling of atacicept: OP. Clinical information on atacicept: CVM.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This research was supported by EMD Serono Research and Development Institute, Inc., a business of Merck KGaA, Darmstadt, Germany.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors are employees of EMD Serono Research and Development Institute, Inc., a business of Merck KGaA, Darmstadt, Germany.\u00a0In 2020 Merck out-licensed atacicept to Vera Therapeutics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Available upon request.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}